ALPN:NSD-Alpine Immune Sciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.58

Change

-0.58 (-6.33)%

Market Cap

USD 0.22B

Volume

0.07M

Avg Analyst Target

USD 21.00 (+144.76%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+2.37 (+0.74%)

USD128.93B 215.22 167.82
BNTX BioNTech SE

+21.37 (+8.23%)

USD62.70B 47.24 36.74
REGN Regeneron Pharmaceuticals, Inc

+3.16 (+0.54%)

USD62.19B 16.62 13.12
VRTX Vertex Pharmaceuticals Incorpo..

-0.25 (-0.13%)

USD50.81B 18.71 13.00
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 41.97
BGNE BeiGene, Ltd

+15.11 (+4.93%)

USD29.15B N/A N/A
GMAB Genmab A/S

+0.21 (+0.48%)

USD28.86B 32.84 3.64
SGEN Seagen Inc

-0.27 (-0.19%)

USD26.06B 40.07 36.19
RPRX Royalty Pharma plc

-0.95 (-2.30%)

USD25.34B 34.40 14.43
ALNY Alnylam Pharmaceuticals, Inc

+1.72 (+0.96%)

USD21.17B N/A N/A

ETFs Containing ALPN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.90% 23% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.90% 23% F 10% F
Trailing 12 Months  
Capital Gain -14.88% 45% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.88% 45% F 15% F
Trailing 5 Years  
Capital Gain -53.97% 31% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.97% 31% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 34.87% 66% D 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.87% 66% D 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 115.58% 22% F 13% F
Risk Adjusted Return 30.17% 54% F 47% F
Market Capitalization 0.22B 38% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.80 46% F 38% F
Price / Cash Flow Ratio 7.28 9% F 43% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -84.58% 30% F 21% F
Return on Invested Capital -53.88% 45% F 15% F
Return on Assets -23.41% 51% F 15% F
Debt to Equity Ratio 12.23% 53% F 69% D+
Technical Ratios  
Short Ratio 3.87 47% F 32% F
Short Percent 9.65% 31% F 20% F
Beta 1.73 30% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector